Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 867Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 441Neoplasms 425Leukemia, Myeloid, Acute 377Lymphoma 356Leukemia 335Melanoma 333Neoplasm Metastasis 321Lung Neoplasms 308Lymphoma, Non-Hodgkin 302Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 281Ovarian Neoplasms 264Pancreatic Neoplasms 249Recurrence 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 239Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 194Carcinoma, Renal Cell 189Head and Neck Neoplasms 187Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has results × Localized Prostate Cancer × Clear all
NCT03315754 2024-12-20

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Steba Biotech S.A.

Phase 2 Active not recruiting
50 enrolled 8 charts
Genitourinary

Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡